Deregulation of cell signaling in cancer

FEBS Letters

Volumn 588, Issue 16, 2014, Pages 2558-2570

  Giancotti, Filippo G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer cell biology; Cell signaling; Targeted therapies; Tumorigenesis

Indexed keywords

CADHERIN; FOCAL ADHESION KINASE; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NOTCH RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR; WNT PROTEIN;

APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER STEM CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEDIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMPLEX FORMATION; CONTACT INHIBITION; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL SARCOMA; GENE SILENCING; GLIOBLASTOMA; HH PATHWAY; HUMAN; LIGAND BINDING; LIPOGENESIS; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MITOGENESIS; NEGATIVE FEEDBACK; NOTCH SIGNALING; OLIGOMERIZATION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; RNA TRANSLATION; SARCOMA; SENESCENCE; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

CANCER CELL BIOLOGY; CELL SIGNALING; TARGETED THERAPIES; TUMORIGENESIS;

ANIMALS; CELL PROLIFERATION; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84905096063     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.02.005     Document Type: Review

References (139)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
2. M.G. Vander Heiden, L.C. Cantley, and C.B. Thompson Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 2009 1029 1033
3. S. Negrini, V.G. Gorgoulis, and T.D. Halazonetis Genomic instability - an evolving hallmark of cancer Nat. Rev. Mol. Cell Biol. 11 2010 220 228
4. S.A. Quezada, K.S. Peggs, T.R. Simpson, and J.P. Allison Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication Immunol. Rev. 241 2011 104 118
5. M. Egeblad, E.S. Nakasone, and Z. Werb Tumors as organs: complex tissues that interface with the entire organism Dev. Cell 18 2010 884 901
6. A. Imamoto, P. Soriano, and P.L. Stein Genetics of signal transduction: tales from the mouse Curr. Opin. Genet. Dev. 4 1994 40 46
7. T. Hunter Signaling-2000 and beyond Cell 100 2000 113 127
8. T. Pawson Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems Cell 116 2004 191 203
9. B. Vogelstein, and K.W. Kinzler Cancer genes and the pathways they control Nat. Med. 10 2004 789 799
10. L. Dehmelt, and P.I. Bastiaens Spatial organization of intracellular communication: insights from imaging Nat. Rev. Mol. Cell Biol. 11 2010 440 452
11. B.N. Kholodenko, J.F. Hancock, and W. Kolch Signalling ballet in space and time Nat. Rev. Mol. Cell Biol. 11 2010 414 426
12. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
13. J. Downward Targeting RAS signalling pathways in cancer therapy Nat. Rev. Cancer 3 2003 11 22
14. D. Vigil, J. Cherfils, K.L. Rossman, and C.J. Der Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10 2010 842 857
15. J. Luo, B.D. Manning, and L.C. Cantley Targeting the PI3K-Akt pathway in human cancer: rationale and promise Cancer Cell 4 2003 257 262
16. B.D. Manning, and L.C. Cantley AKT/PKB signaling: navigating downstream Cell 129 2007 1261 1274
17. A. Di Cristofano, and P.P. Pandolfi The multiple roles of PTEN in tumor suppression Cell 100 2000 387 390
18. L. Chin, J.N. Andersen, and P.A. Futreal Cancer genomics: from discovery science to personalized medicine Nat. Med. 17 2011 297 303
19. B.P. Rubin, M.C. Heinrich, and C.L. Corless Gastrointestinal stromal tumour Lancet 369 2007 1731 1741
20. M.J. Garnett, and R. Marais Guilty as charged: B-RAF is a human oncogene Cancer Cell 6 2004 313 319
21. T.J. Harris, and F. McCormick The molecular pathology of cancer Nat. Rev. Clin. Oncol. 7 2010 251 265
22. P.S. Hammerman et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov. 1 2011 78 89
23. B.M. Gumbiner Cell adhesion: the molecular basis of tissue architecture and morphogenesis Cell 84 1996 345 357
24. F.G. Giancotti, and E. Ruoslahti Integrin signaling Science 285 1999 1028 1032
25. F.G. Giancotti, and G. Tarone Positional control of cell fate through joint integrin/receptor protein kinase signaling Annu. Rev. Cell Dev. Biol. 19 2003 173 206
26. R.O. Hynes Integrins: bidirectional, allosteric signaling machines Cell 110 2002 673 687
27. Y. Pylayeva, K.M. Gillen, W. Gerald, H.E. Beggs, L.F. Reichardt, and F.G. Giancotti Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling J. Clin. Invest. 119 2009 252 266
28. J.B. Bolen, A. Veillette, A.M. Schwartz, V. DeSeau, and N. Rosen Activation of pp60c-src protein kinase activity in human colon carcinoma Proc. Natl. Acad. Sci. U.S.A. 84 1987 2251 2255
29. W. Xue et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma Genes Dev. 22 2008 1439 1444
30. W. Li et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus Cell 140 2010 477 490
31. N.G. Kim, E. Koh, X. Chen, and B.M. Gumbiner E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components Proc. Natl. Acad. Sci. U.S.A. 108 2011 11930 11935
32. K. Harvey, and N. Tapon The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network Nat. Rev. Cancer 7 2007 182 191
33. D. Pan The hippo signaling pathway in development and cancer Dev. Cell 19 2010 491 505
34. G. Halder, and R.L. Johnson Hippo signaling: growth control and beyond Development 138 2011 9 22
35. H. Clevers Wnt/beta-catenin signaling in development and disease Cell 127 2006 469 480
36. T. Okada, L. You, and F.G. Giancotti Shedding light on Merlin's wizardry Trends Cell Biol. 17 2007 222 229
37. U. Cavallaro, and G. Christofori Cell adhesion and signalling by cadherins and Ig-CAMs in cancer Nat. Rev. Cancer 4 2004 118 132
38. M. Bott et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma Nat. Genet. 43 2011 668 672
39. L. Zender et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach Cell 125 2006 1253 1267
40. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484
41. R. Zoncu, A. Efeyan, and D.M. Sabatini MTOR: from growth signal integration to cancer, diabetes and ageing Nat. Rev. Mol. Cell Biol. 12 2011 21 35
42. X.M. Ma, and J. Blenis Molecular mechanisms of mTOR-mediated translational control Nat. Rev. Mol. Cell Biol. 10 2009 307 318
43. P.P. Hsu et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling Science 332 2011 1317 1322
44. Y. Yu et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling Science 332 2011 1322 1326
45. O. Warburg On respiratory impairment in cancer cells Science 124 1956 269 270
46. R.A. Cairns, I.S. Harris, and T.W. Mak Regulation of cancer cell metabolism Nat. Rev. Cancer 11 2011 85 95
47. J.D. Gordan, C.B. Thompson, and M.C. Simon HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation Cancer Cell 12 2007 108 113
48. E.R. Mardis et al. Recurring mutations found by sequencing an acute myeloid leukemia genome N. Engl. J. Med. 361 2009 1058 1066
49. H. Yan et al. IDH1 and IDH2 mutations in gliomas N. Engl. J. Med. 360 2009 765 773
50. R.G. Verhaak et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
51. L. Dang et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
52. P.S. Ward et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 2010 225 234
53. M.E. Figueroa et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 2010 553 567
54. K. Moran-Crusio et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation Cancer Cell 20 2011 11 24
55. C. Quivoron et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis Cancer Cell 20 2011 25 38
56. B. Levine, and G. Kroemer Autophagy in the pathogenesis of disease Cell 132 2008 27 42
57. N. Mizushima, B. Levine, A.M. Cuervo, and D.J. Klionsky Autophagy fights disease through cellular self-digestion Nature 451 2008 1069 1075
58. J.Y. Guo et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis Genes Dev. 25 2011 460 470
59. S. Yang et al. Pancreatic cancers require autophagy for tumor growth Genes Dev. 25 2011 717 729
60. R. Mathew, and E. White Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night Curr. Opin. Genet. Dev. 21 2011 113 119
61. P. Nurse A long twentieth century of the cell cycle and beyond Cell 100 2000 71 78
62. A.W. Murray Recycling the cell cycle: cyclins revisited Cell 116 2004 221 234
63. D. Guardavaccaro, and M. Pagano Stabilizers and destabilizers controlling cell cycle oscillators Mol. Cell 22 2006 1 4
64. C.J. Sherr Principles of tumor suppression Cell 116 2004 235 246
65. S. van den Heuvel, and N.J. Dyson Conserved functions of the pRB and E2F families Nat. Rev. Mol. Cell Biol. 9 2008 713 724
66. R.C. Sears, and J.R. Nevins Signaling networks that link cell proliferation and cell fate J. Biol. Chem. 277 2002 11617 11620
67. S.W. Blain, H.I. Scher, C. Cordon-Cardo, and A. Koff P27 as a target for cancer therapeutics Cancer Cell 3 2003 111 115
68. J. Massague G1 cell-cycle control and cancer Nature 432 2004 298 306
69. D. Frescas, and M. Pagano Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer Nat. Rev. Cancer 8 2008 438 449
70. M.A. Velasco-Velazquez, Z. Li, M. Casimiro, E. Loro, N. Homsi, and R.G. Pestell Examining the role of cyclin D1 in breast cancer Future Oncol. 7 2011 753 765
71. L. Soucek, and G.I. Evan The ups and downs of Myc biology Curr. Opin. Genet. Dev. 20 2010 91 95
72. J. Massague TGFbeta in cancer Cell 134 2008 215 230
73. Y. Shi, and J. Massague Mechanisms of TGF-beta signaling from cell membrane to the nucleus Cell 113 2003 685 700
74. S.W. Lowe, E. Cepero, and G. Evan Intrinsic tumour suppression Nature 432 2004 307 315
75. K.H. Vousden, and C. Prives Blinded by the light: the growing complexity of p53 Cell 137 2009 413 431
76. T. Riley, E. Sontag, P. Chen, and A. Levine Transcriptional control of human p53-regulated genes Nat. Rev. Mol. Cell Biol. 9 2008 402 412
77. T.G. Cotter Apoptosis and cancer: the genesis of a research field Nat. Rev. Cancer 9 2009 501 507
78. N.N. Danial, and S.J. Korsmeyer Cell death: critical control points Cell 116 2004 205 219
79. K.W. Yip, and J.C. Reed Bcl-2 family proteins and cancer Oncogene 27 2008 6398 6406
80. F. Llambi, and D.R. Green Apoptosis and oncogenesis: give and take in the BCL-2 family Curr. Opin. Genet. Dev. 21 2011 12 20
81. J.E. Chipuk, and D.R. Green How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 18 2008 157 164
82. X. Jiang, and X. Wang Cytochrome C-mediated apoptosis Annu. Rev. Biochem. 73 2004 87 106
83. M. Kurokawa, and S. Kornbluth Caspases and kinases in a death grip Cell 138 2009 838 854
84. T. Kuilman, C. Michaloglou, W.J. Mooi, and D.S. Peeper The essence of senescence Genes Dev. 24 2010 2463 2479
85. G.I. Evan, and F. d'Adda di Fagagna Cellular senescence: hot or what? Curr. Opin. Genet. Dev. 19 2009 25 31
86. M.B. Kastan, and J. Bartek Cell-cycle checkpoints and cancer Nature 432 2004 316 323
87. A. Ciccia, and S.J. Elledge The DNA damage response: making it safe to play with knives Mol. Cell 40 2010 179 204
88. G.P. Gupta, and J. Massague Cancer metastasis: building a framework Cell 127 2006 679 695
89. C.L. Chaffer, and R.A. Weinberg A perspective on cancer cell metastasis Science 331 2011 1559 1564
90. B. Goldstein, and I.G. Macara The PAR proteins: fundamental players in animal cell polarization Dev. Cell 13 2007 609 622
91. J. Debnath, and J.S. Brugge Modelling glandular epithelial cancers in three-dimensional cultures Nat. Rev. Cancer 5 2005 675 688
92. C.M. Nelson, and M.J. Bissell Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer Annu. Rev. Cell Dev. Biol. 22 2006 287 309
93. A. Wodarz, and I. Nathke Cell polarity in development and cancer Nat. Cell Biol. 9 2007 1016 1024
94. P.O. Humbert, N.A. Grzeschik, A.M. Brumby, R. Galea, I. Elsum, and H.E. Richardson Control of tumourigenesis by the Scribble/Dlg/Lgl polarity module Oncogene 27 2008 6888 6907
95. L. Huang, and S.K. Muthuswamy Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators Curr. Opin. Genet. Dev. 20 2010 41 50
96. J. Yang, and R.A. Weinberg Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis Dev. Cell 14 2008 818 829
97. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial- mesenchymal transitions in development and disease Cell 139 2009 871 890
98. H. Peinado, D. Olmeda, and A. Cano Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7 2007 415 428
99. A. Ventura, and T. Jacks MicroRNAs and cancer: short RNAs go a long way Cell 136 2009 586 591
100. K. Polyak, and R.A. Weinberg Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits Nat. Rev. Cancer 9 2009 265 273
101. P. Friedl, and K. Wolf Plasticity of cell migration: a multiscale tuning model J. Cell Biol. 188 2010 11 19
102. A.J. Ridley, M.A. Schwartz, K. Burridge, R.A. Firtel, M.H. Ginsberg, G. Borisy, J.T. Parsons, and A.R. Horwitz Cell migration: integrating signals from front to back Science 302 2003 1704 1709
103. A.B. Jaffe, and A. Hall Rho GTPases: biochemistry and biology Annu. Rev. Cell Dev. Biol. 21 2005 247 269
104. V. Sanz-Moreno, and C.J. Marshall The plasticity of cytoskeletal dynamics underlying neoplastic cell migration Curr. Opin. Cell Biol. 22 2010 690 696
105. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
106. P.B. Gupta, C.L. Chaffer, and R.A. Weinberg Cancer stem cells: mirage or reality? Nat. Med. 15 2009 1010 1012
107. H. Clevers The cancer stem cell: premises, promises and challenges Nat. Med. 17 2011 313 319
108. P.A. Beachy, S.S. Karhadkar, and D.M. Berman Tissue repair and stem cell renewal in carcinogenesis Nature 432 2004 324 331
109. S. Artavanis-Tsakonas, and M.A. Muskavitch Notch: the past, the present, and the future Curr. Top. Dev. Biol. 92 2010 1 29
110. M. Roy, W.S. Pear, and J.C. Aster The multifaceted role of Notch in cancer Curr. Opin. Genet. Dev. 17 2007 52 59
111. S.C. Goetz, and K.V. Anderson The primary cilium: a signalling centre during vertebrate development Nat. Rev. Genet. 11 2010 331 344
112. L. Mishra, R. Derynck, and B. Mishra Transforming growth factor-beta signaling in stem cells and cancer Science 310 2005 68 71
113. M.E. Valk-Lingbeek, S.W. Bruggeman, and M. van Lohuizen Stem cells and cancer; the polycomb connection Cell 118 2004 409 418
114. M.D. Resh Trafficking and signaling by fatty-acylated and prenylated proteins Nat. Chem. Biol. 2 2006 584 590
115. C. Wicking, I. Smyth, and A. Bale The hedgehog signalling pathway in tumorigenesis and development Oncogene 18 1999 7844 7851
116. C. Sawyers Targeted cancer therapy Nature 432 2004 294 297
117. J. Jonkers, and A. Berns Oncogene addiction: sometimes a temporary slavery Cancer Cell 6 2004 535 538
118. S.V. Sharma, and J. Settleman Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes Dev. 21 2007 3214 3231
119. I.B. Weinstein Cancer. Addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64
120. S.V. Sharma, D.W. Bell, J. Settleman, and D.A. Haber Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 7 2007 169 181
121. C.A. Hudis Trastuzumab-mechanism of action and use in clinical practice N. Engl. J. Med. 357 2007 39 51
122. G. Bollag et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
123. P.B. Chapman et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
124. D.W. Sherbenou, and B.J. Druker Applying the discovery of the Philadelphia chromosome J. Clin. Invest. 117 2007 2067 2074
125. P.I. Poulikakos, and N. Rosen Mutant BRAF melanomas-dependence and resistance Cancer Cell 19 2011 11 15
126. J.S. Sebolt-Leopold, and J.M. English Mechanisms of drug inhibition of signalling molecules Nature 441 2006 457 462
127. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
128. M. Shackleton, E. Quintana, E.R. Fearon, and S.J. Morrison Heterogeneity in cancer: cancer stem cells versus clonal evolution Cell 138 2009 822 829
129. M. Dean, T. Fojo, and S. Bates Tumour stem cells and drug resistance Nat. Rev. Cancer 5 2005 275 284
130. M. Savona, and M. Talpaz Getting to the stem of chronic myeloid leukaemia Nat. Rev. Cancer 8 2008 341 350
131. S.A. Martin, C.J. Lord, and A. Ashworth DNA repair deficiency as a therapeutic target in cancer Curr. Opin. Genet. Dev. 18 2008 80 86
132. C.A. Klein Framework models of tumor dormancy from patient-derived observations Curr. Opin. Genet. Dev. 21 2011 42 49
133. F.G. Giancotti Mechanisms governing metastatic dormancy and reactivation Cell 155 2013 750 764
134. J. Heyer, L.N. Kwong, S.W. Lowe, and L. Chin Non-germline genetically engineered mouse models for translational cancer research Nat. Rev. Cancer 10 2010 470 480
135. M.R. Stratton Exploring the genomes of cancer cells: progress and promise Science 331 2011 1553 1558
136. J.A. Joyce, and J.W. Pollard Microenvironmental regulation of metastasis Nat. Rev. Cancer 9 2009 239 252
137. N. Ferrara, R.D. Mass, C. Campa, and R. Kim Targeting VEGF-A to treat cancer and age-related macular degeneration Annu. Rev. Med. 58 2007 491 504
138. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell 140 2010 883 899
139. H. Varmus The new era in cancer research Science 312 2006 1162 1165